Dr. Reddy's Share Price Gains Following Q4 Profit Beat
The company's revenue rose by 20% to Rs 8,528 crore, compared to the Bloomberg estimate of Rs 8,359.7 crore.
Dr. Reddy's Laboratories Ltd.'s shares rose over 2% after reporting fourth-quarter results for fiscal 2025. The pharmaceutical giant's consolidated net profit increased 22%, surpassing analysts' expectations.
The company announced a net profit of Rs 1,593 crore for the quarter ending March 2025, exceeding the Rs 1,459 crore forecast by analysts tracked by Bloomberg. This strong performance was reflected in the revenue figures, which rose by 20% to Rs 8,528 crore, compared to the Bloomberg estimate of Rs 8,359.7 crore.
Dr. Reddy's Ebitda climbed 13.3% to Rs 2,074.7 crore, although it fell short of the estimated Rs 2,268.6 crore. The company's margin stood at 24.3%, slightly below the Bloomberg estimate of 27.1%.
Dr. Reddy's Laboratories was founded in 1984 and the company specialises in the production of generic medications, active pharmaceutical ingredients, and biosimilars. The company operates globally, with a strong presence in markets such as the United States, Europe, and India.
Dr. Reddy's Share Price Today
The scrip rose as much as 2.51% to Rs 1,184 apiece. It pared gains to trade 0.35% higher at Rs 1,159.90 apiece, as of 09:49 a.m. This compares to a 2.51% advance in the NSE Nifty 50.
It has fallen 1.85% in the last 12 months. Total traded volume so far in the day stood at 4.6 times its 30-day average. The relative strength index was at 49.
Out of 38 analysts tracking the company, 15 maintain a 'buy' rating, 11 recommend a 'hold' and 12 suggest 'sell', according to Bloomberg data. The average 12-month analysts' consensus price target implies an upside of 9.4%.
